Friday, November 17, 2017 9:15:50 AM
Alternative Names: MCT-465
Latest Information Update: 04 Nov 2017
At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Antivirals; RNA
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunostimulants; T lymphocyte stimulants; Toll-like receptor agonists
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
Preclinical Viral hepatitis
No development reported Cancer; Liver cancer
Discontinued Influenza virus infections
Most Recent Events
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in USA (Parenteral)
25 Aug 2014 Pharmacodynamics data from preclinical studies in Cancer and Viral hepatitis released by MultiCell Technologies
http://adisinsight.springer.com/drugs/800023642
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM